Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Corneat Vision Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These legal challenges are distributed across 2 distinct examiners, which requires a strategy that accounts for different individual perspectives at the USPTO. Furthermore, the involvement of 2 distinct art units indicates that the portfolio's current activity spans multiple specialized divisions within the office.
The busiest examiner, TRUONG, QUANGLONG N, is currently handling 1 pending office action. This matter is part of the current workload within the Biotechnology & Pharmaceuticals technology area. The current distribution suggests that the company's technical focus is broad enough to be categorized into different specialized divisions at the USPTO.
Managing 2 pending office actions across 2 distinct examiners requires a coordinated effort to ensure consistency. Since TRUONG, QUANGLONG N oversees 1 pending office action, the practitioner can focus on this specific relationship while also monitoring the other active matter. This distribution across 2 distinct art units provides a diversified exposure to USPTO examination practices.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRUONG, QUANGLONG N | 1 | 78.8% | +23.6% |
| FUBARA, BLESSING M | 1 | 62.2% | +34.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17640920 | GRAFT PATCH FOR THE TREATMENT OF MYOPIA AND OPHTHALMIC CONDITIONS | TRUONG, QUANGLONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17633678 | GINGIVAL GRAFT | FUBARA, BLESSING M | 100d overdue |
| 17640920 | GRAFT PATCH FOR THE TREATMENT OF MYOPIA AND OPHTHALMIC CONDITIONS | TRUONG, QUANGLONG N | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17640920 | GRAFT PATCH FOR THE TREATMENT OF MYOPIA AND OPHTHALMIC CONDITIONS | TRUONG, QUANGLONG N | 1615 | §103§112 | Non-Final OA | — | Pending | Mar 07, 2022 |
| 17633678 | GINGIVAL GRAFT | FUBARA, BLESSING M | 1613 | §103 | Final Rejection | 100d overdue | Pending | Feb 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial